Adial Pharmaceuticals Inc Stock Price, News & Analysis

Adial Pharmaceuticals has secured $1,255,000 in funding to bolster its clinical trial initiatives for the non-opioid pain treatment candidate PNV-5030. This includes $800,000 from a private placement at $4.00 per share and $455,000 from the exercise of stock options by Mark Howard Peikin, the Chief Strategy Officer. Peikin's cash exercise supports drug development, enhancing Adial's financial position for ongoing and future trials, specifically the pivotal Phase 3 trial of its lead drug for Alcohol Use Disorder (AUD).

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced a conference call on November 18, 2021, at 11:00 A.M. ET to provide updates on its clinical trials and business progress. The company is developing AD04, a serotonin-3 receptor antagonist for treating Alcohol Use Disorder (AUD). AD04 is in a pivotal Phase 3 trial and has shown promising Phase 2b results, indicating a significant reduction in drinking frequency and quantity with no major safety concerns. Adial also explores treatments for other addictive disorders and develops adenosine analogs for pain management.

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the appointment of Cary J. Claiborne to its Board of Directors, expanding the board to seven members. Claiborne brings extensive experience, having previously served as CFO of Indivior PLC and Sucampo Pharmaceuticals. His expertise in governance and finance is expected to support Adial as it advances its Phase 3 clinical trial of AD04 for alcohol use disorder and prepares for potential commercialization. Adial aims to leverage Claiborne's track record to enhance its corporate governance and strategic initiatives.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced promising pre-clinical results for PNV-5030, a potential pain treatment. The compound showed over 1000-fold selectivity over the adenosine A1 receptor and significantly reduced pain in a mouse model. When combined with morphine, PNV-5030 achieved similar pain reduction to higher morphine doses. Purnovate, a subsidiary of Adial, plans to advance PNV-5030 into clinical trials in 2022, aiming to provide an alternative or complement to opioid use.

Adial Pharmaceuticals announced positive pre-clinical results for PNV-5030, indicating its potential to reduce opioid use and alleviate pain. PNV-5030 exhibited over 1000-fold selectivity over the adenosine A1 receptor and demonstrated superior solubility compared to other compounds in its class. In mouse models, PNV-5030 alone provided significant pain relief similar to low doses of morphine, and remarkably, when combined with morphine, it achieved pain relief equivalent to a higher morphine dose. The company plans to advance PNV-5030 into clinical trials in 2022.

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has announced that CEO William Stilley will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021, at 9:45 am ET. The conference will take place at the Wyndham Grand Hotel in Jupiter, Florida, where Stilley will also hold one-on-one meetings with investors. Adial is focused on therapies for addiction, with its lead product AD04 currently in a pivotal Phase 3 clinical trial for Alcohol Use Disorder. Live webcast details can be found on Adial's investor relations website.

Adial Pharmaceuticals (NASDAQ:ADIL;ADILW) has been invited to present at the virtual MicroCap Rodeo Fall Harvest - Best Ideas Conference on October 5, 2021, at 2:30 PM ET. CEO William Stilley will present live, followed by one-on-one meetings during the event. Adial focuses on developing therapies for addiction, with its lead product, AD04, currently in a pivotal Phase 3 clinical trial for Alcohol Use Disorder. The company aims to address various addictive disorders, including Opioid Use Disorder.

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has reported that over 50% of patients have completed the ONWARD™ Phase 3 trial for AD04, targeting Alcohol Use Disorder (AUD) based on specific genetic profiles. This 24-week trial, involving 25 sites across Scandinavia and Eastern Europe, aims to analyze the efficacy and safety of AD04. With 303 patients enrolled, the study anticipates a favorable safety profile and is expected to meet its primary endpoint by early 2022. The trial is designed to complement behavioral therapy, enhancing the potential treatment landscape for AUD.

Adial Pharmaceuticals has announced a research collaboration with Dr. Mark Roeser from the University of Virginia to create new adenosine formulations for transdermal application, targeting wound healing. Under the agreement, Purnovate will supply lead compounds while Dr. Roeser's team evaluates them for efficacy and optimal absorption. The University will fund pre-clinical studies, with jointly developed intellectual property. The pressure ulcer wound market is projected to hit $11.2 billion by 2026, highlighting significant market potential for these therapies.